Arrowhead Pharmaceuticals (ARWR) Non-Current Deffered Revenue (2015 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 10 years of Non-Current Deffered Revenue data on file, last reported at $48.6 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.6 million (changed N/A YoY) and the FY2022 annual result came in at $56.0 million, down 57.45% from the prior year.
• Non-Current Deffered Revenue retreated to $48.6 million in Q1 2026, from $53.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $89.8 million in Q1 2022 to a low of $1.1 million in Q1 2023.
• A 4-year average of $51.6 million and a median of $53.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slipped 10.77% — and 2023, when it tumbled 98.8%.
• Tracing ARWR's Non-Current Deffered Revenue over 4 years: stood at $40.8 million in 2022, then tumbled by 97.36% to $1.1 million in 2023, then soared by 4906.98% to $53.8 million in 2025, then decreased by 9.68% to $48.6 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $48.6 million (Q1 2026), $53.8 million (Q4 2025), and $1.1 million (Q1 2023), per Business Quant data.